Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.68

-2.4%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5351)	1/7/2002 9:52:50 AM
From: rkrw	Read Replies (2) of 52153

<<<the Actimmune Fast Track designation - although the latter news might not have been saved up for the conference).>>> Not sure you caught this which was tucked into the itmn announcement.... "In addition, the Company reported that in its ongoing Phase III trial for IPF, approximately 60% of the trial is complete in terms of patient treatment days. Furthermore, less than 5% of patients have withdrawn from the study prior to meeting the primary endpoint. This retention rate is well within the assumptions underlying the statistical power and sample size of the 330-patient trial. Dr. Harkonen also stated, ``We are very pleased with this high level of patient retention as of January and expect that patient retention going forward will continue to be strong. We would like to thank all participating investigators, coordinators and patients for their tremendous commitment and dedication to this trial.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next